Cwm LLC Lowers Position in Ventyx Biosciences, Inc. $VTYX

Cwm LLC lessened its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 66.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 19,279 shares of the company’s stock after selling 37,866 shares during the period. Cwm LLC’s holdings in Ventyx Biosciences were worth $60,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in VTYX. Wealth Enhancement Advisory Services LLC lifted its position in shares of Ventyx Biosciences by 21.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock valued at $62,000 after buying an additional 5,174 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in Ventyx Biosciences during the second quarter valued at approximately $34,000. Pallas Capital Advisors LLC bought a new position in shares of Ventyx Biosciences in the second quarter worth approximately $38,000. Engineers Gate Manager LP purchased a new stake in shares of Ventyx Biosciences in the second quarter worth $42,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Ventyx Biosciences by 104.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 46,711 shares of the company’s stock valued at $100,000 after purchasing an additional 23,828 shares during the period. Institutional investors own 97.88% of the company’s stock.

Insiders Place Their Bets

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Nuss sold 12,675 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider directly owned 489,481 shares in the company, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 18.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on VTYX shares. UBS Group reaffirmed a “neutral” rating and issued a $14.00 target price (down previously from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Oppenheimer lowered shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Clear Str downgraded shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Finally, Piper Sandler downgraded Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price on the stock. in a research report on Thursday, January 8th. Eight research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of “Reduce” and an average target price of $14.00.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $13.89 on Tuesday. The firm has a market capitalization of $991.19 million, a price-to-earnings ratio of -9.26 and a beta of 1.23. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $25.00. The company has a 50-day moving average of $9.88 and a 200 day moving average of $5.81.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. On average, equities analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.